Depo-Provera and Meningiomas: Consensus Recommendations From Europe

“A combined effort was initiated between Neurosurgical, Gynaecological and Endocrinological societies of Belgium to gather relevant information regarding sex hormone therapies and meningioma. After complete literature review, consensual recommendations were established,” states Sebastien Froelich, Department of Neurosurgery, Leuven, Belgium. What did Dr. Sebastien Froelich report in the 2025 article “Recommendations on the management of meningioma [...]

2025-03-24T10:45:39-07:00March 24th, 2025|Meningioma Help Desk, News|0 Comments

Meningioma Subtotal Resection/Reoccurrence: Radiation versus Observation versus Re-resection

“These findings indicate that for patients with benign meningioma desiring to avoid the high stroke risk of fractionated proton-photon RT (radiotherapy), SRS (single-fraction stereotactic radiosurgery (SRS) has a comparable stroke risk profile to observation," states Dr. Jeremy N. Ciporen, Department of Neurological Surgery, Oregon Health and Science University. Greg Vigna, MD, JD, national pharmaceutical injury [...]

2025-01-06T15:38:57-07:00November 16th, 2024|Meningioma Help Desk, News|0 Comments

Depo-Provera and Meningioma: Pathology Examination and Progesterone Receptor Expression

“High progesterone receptor positivity was linked to low grade tumors. Meningioma grade and many subtypes can be identified with the use of progesterone receptor expression, particularly in cases that are borderline,” states Dr. Assad Albayati. Greg Vigna, MD, JD, national pharmaceutical injury attorney, states, “In this study, like others, 79.3 % of Grade I meningiomas, [...]

2024-11-11T23:35:06-07:00November 11th, 2024|Meningioma Help Desk, News|0 Comments

Vigna Law Group: Craniotomy Help Desk, Sorting Out the Evidence

“My law firm’s focus is the representation of women who used Depo-Provera and have required brain surgery for meningiomas that are progesterone receptor expression positive," states Greg Vigna, MD, JD, Board Certified PM&R. Greg Vigna, MD, JD, national pharmaceutical injury attorney, states, “Recent population studies from Europe describe a 5.5x risk of developing meningiomas in [...]

2024-11-07T20:30:18-07:00November 1st, 2024|Meningioma Help Desk, News|0 Comments

Depo-Provera Menigiomas: PET Scan, Operative Planning, and Prognosis

“Unfortunately, biological aggressiveness … can only be investigated after surgery. Differentiation between low- and high-grade meningiomas using conventional MRI is difficult. Imaging techniques that enable noninvasive, preoperative assessment of tumor biology and WHO grade could potentially be helpful in surgical planning," states Dr. K. Mariam Slot, Neurosurgeon, Amsterdam University Medical Centers. What did Dr. K [...]

2024-11-07T20:17:21-07:00October 25th, 2024|Meningioma Help Desk, News|0 Comments

Depo-Provera Incidental Menigiomas: No Consensus on Optimal Management

“Incidental diagnosis of a meningioma is an injury in the 50% that are managed with active monitoring because the need for periodic diagnostic imaging, medical surveillance, and reasonable uncertainty as to the future is an injury,” states Dr. Greg Vigna, national neurological injury attorney and Board Certified Physical Medicine and Rehabilitation physician. What did Dr. Abdurrahman [...]

2024-11-07T20:15:23-07:00October 24th, 2024|Meningioma Help Desk, News|0 Comments
Go to Top